- vecho Biotechnology (AVE) has received ethics approval for its phase one clinical trial to characterise the absorption profile of cannabidiol (CBD) in healthy volunteers
- The research will also take place at CMAX in Adelaide and measure the safety and absorption profile of the CBD product
- The study will be a cross-over design, comparing the absorption of CBD after consumption of soft-gel capsules at two different doses of 75 milligrams and 150 milligrams
- The data will then form an integral part of a future TGA submission and drug label
- The company says increasing the absorption of cannabinoids will support the development of differentiated products on the market, with potential for reduced cost to patients
- Avecho shares are trading flat at 2.2 cents
